NCT06696807View on ClinicalTrials.gov

Immunomodulatory Therapy & VSA

CompletedOBSERVATIONAL
Enrollment

71

Participants

Timeline

Start Date

October 1, 2018

Primary Completion Date

April 1, 2024

Study Completion Date

May 1, 2024

Conditions
Vasospastic Angina
Interventions
DRUG

glucocorticosteroids and/or intravenous immunoglobulin

methylprednisolone: 20-200mg/day intravenous immunoglobulin: 5-20 g/day

Trial Locations (1)

430030

Tongji Hospital, Wuhan

All Listed Sponsors
lead

Dao Wen Wang

OTHER

NCT06696807 - Immunomodulatory Therapy & VSA | Biotech Hunter | Biotech Hunter